MIST
insider transactionsMilestone Pharmaceuticals Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-523.1K
0 buy · 523.1K sell
Net value · 365d
-$1.2M
$0 in · $1.2M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
13
0 buy · 523.1K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
77.0K sh
Own New
-
Grant·A
Director
$0
77.0K sh
Own New
-
Grant·A
Director
$0
77.0K sh
Own New
-
Grant·A
Director
$0
77.0K sh
Own New
-
Grant·A
Director
$0
77.0K sh
Own New
-
Grant·A
Director
$0
77.0K sh
Own New
-
Grant·A
Director
$0
77.0K sh
Own New
-
Sell·S
Joseph Oliveto KEY
President and CEO · 10b5-1
$82.5K
36.5K sh · $2.26
Own -8%
-
Grant·A
Chief Operating Officer
$0
136.0K sh
Own New
-
Grant·A
Chief Operating Officer
$0
204.0K sh
Own New
-
Grant·A
Chief Commercial Officer
$0
136.0K sh
Own New
-
Grant·A
Chief Commercial Officer
$0
204.0K sh
Own New
-
Grant·A
Joseph Oliveto KEY
President and CEO
$0
453.0K sh
Own New
-
Grant·A
Joseph Oliveto KEY
President and CEO
$0
679.0K sh
Own New
-
Grant·A
Amit Hasija KEY
CFO & EVP of Corp. Development
$0
136.0K sh
Own New
-
Grant·A
Amit Hasija KEY
CFO & EVP of Corp. Development
$0
204.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
136.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
204.0K sh
Own New
-
Grant·A
Chief Operating Officer
$0
204.0K sh
Own New
-
Grant·A
Chief Commercial Officer
$0
204.0K sh
Own New
-
Grant·A
Joseph Oliveto KEY
President and CEO
$0
679.0K sh
Own New
-
Grant·A
Amit Hasija KEY
CFO & EVP of Corp. Development
$0
204.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
204.0K sh
Own New
-
Exercise·M
Chief Operating Officer
$0
20.1K sh
Own +50%
-
Sell·S
Chief Operating Officer
$23.6K
12.2K sh · $1.93
Own -20%
-
Exercise·M
Chief Operating Officer
—
20.1K sh
Own +48%
-
Exercise·M
Chief Commercial Officer
$0
20.1K sh
Own +50%
-
Sell·S
Chief Commercial Officer
$21.6K
11.2K sh · $1.93
Own -5%
-
Exercise·M
Chief Commercial Officer
—
20.1K sh
Own +10%
-
Exercise·M
Joseph Oliveto KEY
President and CEO
$0
66.6K sh
Own +50%
-
Sell·S
Joseph Oliveto KEY
President and CEO
$66.6K
34.5K sh · $1.93
Own -7%
-
Exercise·M
Joseph Oliveto KEY
President and CEO
—
66.6K sh
Own +15%
-
Exercise·M
Amit Hasija KEY
CFO & EVP of Corp. Development
$0
20.1K sh
Own +50%
-
Sell·S
Amit Hasija KEY
CFO & EVP of Corp. Development
$23.6K
12.2K sh · $1.93
Own -11%
-
Exercise·M
Amit Hasija KEY
CFO & EVP of Corp. Development
—
20.1K sh
Own +22%
-
Exercise·M
Chief Medical Officer
$0
20.1K sh
Own +50%
-
Sell·S
Chief Medical Officer
$23.6K
12.2K sh · $1.93
Own -10%
-
Exercise·M
Chief Medical Officer
—
20.1K sh
Own +19%
-
Sell·S
Joseph Oliveto KEY
President and CEO · 10b5-1
$96.8K
43.0K sh · $2.25
Own -12%
-
Sell·S
Joseph Oliveto KEY
President and CEO · 10b5-1
$1.1K
500 sh · $2.25
Own -0%
-
Grant·A
Director
$0
40.0K sh
Own New
-
Sell·S
Chief Operating Officer
$134.6K
58.0K sh · $2.32
Own -58%
-
Sell·S
Chief Commercial Officer
$124.3K
53.6K sh · $2.32
Own -21%
-
Sell·S
Joseph Oliveto KEY
President and CEO
$308.7K
133.1K sh · $2.32
Own -23%
-
Sell·S
Amit Hasija KEY
CFO & EVP of Corp. Development
$134.6K
58.0K sh · $2.32
Own -39%
-
Sell·S
Chief Medical Officer
$134.6K
58.0K sh · $2.32
Own -36%
-
Grant·A
Chief Operating Officer
$0
100.0K sh
Own New
-
Grant·A
Chief Operating Officer
—
100.0K sh
Own New
-
Grant·A
Chief Commercial Officer
$0
100.0K sh
Own New
-
Grant·A
Chief Commercial Officer
—
100.0K sh
Own +67%
-
Grant·A
Joseph Oliveto KEY
President and CEO
$0
280.0K sh
Own New
-
Grant·A
Joseph Oliveto KEY
President and CEO
—
280.0K sh
Own +92%
-
Grant·A
Amit Hasija KEY
CFO & EVP of Corp. Development
$0
100.0K sh
Own New
-
Grant·A
Amit Hasija KEY
CFO & EVP of Corp. Development
—
100.0K sh
Own +200%
-
Grant·A
Chief Medical Officer
$0
100.0K sh
Own New
-
Grant·A
Chief Medical Officer
—
100.0K sh
Own +158%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 10, 2026 | Robert James Wills | Grant A | 77.0K | $0 |
| Jun 10, 2026 | Andrew Saik | Grant A | 77.0K | $0 |
| Jun 10, 2026 | Michael John Tomsicek | Grant A | 77.0K | $0 |
| Jun 10, 2026 | Joseph C Papa | Grant A | 77.0K | $0 |
| Jun 10, 2026 | Lisa M. Giles | Grant A | 77.0K | $0 |
| Jun 10, 2026 | Seth H. Z. Fischer | Grant A | 77.0K | $0 |
| Jun 10, 2026 | Stuart Duty | Grant A | 77.0K | $0 |
| Apr 16, 2026 | Joseph Oliveto KEY 10b5-1 | Sell S | 36.5K | $82.5K |
| Feb 2, 2026 | Jeffrey Edward Nelson | Grant A | 136.0K | $0 |
| Feb 2, 2026 | Jeffrey Edward Nelson | Grant A | 204.0K | $0 |
| Feb 2, 2026 | Lorenz Muller | Grant A | 136.0K | $0 |
| Feb 2, 2026 | Lorenz Muller | Grant A | 204.0K | $0 |
| Feb 2, 2026 | Joseph Oliveto KEY | Grant A | 453.0K | $0 |
| Feb 2, 2026 | Joseph Oliveto KEY | Grant A | 679.0K | $0 |
| Feb 2, 2026 | Amit Hasija KEY | Grant A | 136.0K | $0 |
| Feb 2, 2026 | Amit Hasija KEY | Grant A | 204.0K | $0 |
| Feb 2, 2026 | David Bharucha | Grant A | 136.0K | $0 |
| Feb 2, 2026 | David Bharucha | Grant A | 204.0K | $0 |
| Feb 2, 2026 | Jeffrey Edward Nelson | Grant A | 204.0K | $0 |
| Feb 2, 2026 | Lorenz Muller | Grant A | 204.0K | $0 |
| Feb 2, 2026 | Joseph Oliveto KEY | Grant A | 679.0K | $0 |
| Feb 2, 2026 | Amit Hasija KEY | Grant A | 204.0K | $0 |
| Feb 2, 2026 | David Bharucha | Grant A | 204.0K | $0 |
| Jan 26, 2026 | Jeffrey Edward Nelson | Exercise M | 20.1K | $0 |
| Jan 26, 2026 | Jeffrey Edward Nelson | Sell S | 12.2K | $23.6K |
| Jan 26, 2026 | Jeffrey Edward Nelson | Exercise M | 20.1K | — |
| Jan 26, 2026 | Lorenz Muller | Exercise M | 20.1K | $0 |
| Jan 26, 2026 | Lorenz Muller | Sell S | 11.2K | $21.6K |
| Jan 26, 2026 | Lorenz Muller | Exercise M | 20.1K | — |
| Jan 26, 2026 | Joseph Oliveto KEY | Exercise M | 66.6K | $0 |
| Jan 26, 2026 | Joseph Oliveto KEY | Sell S | 34.5K | $66.6K |
| Jan 26, 2026 | Joseph Oliveto KEY | Exercise M | 66.6K | — |
| Jan 26, 2026 | Amit Hasija KEY | Exercise M | 20.1K | $0 |
| Jan 26, 2026 | Amit Hasija KEY | Sell S | 12.2K | $23.6K |
| Jan 26, 2026 | Amit Hasija KEY | Exercise M | 20.1K | — |
| Jan 26, 2026 | David Bharucha | Exercise M | 20.1K | $0 |
| Jan 26, 2026 | David Bharucha | Sell S | 12.2K | $23.6K |
| Jan 26, 2026 | David Bharucha | Exercise M | 20.1K | — |
| Jan 8, 2026 | Joseph Oliveto KEY 10b5-1 | Sell S | 43.0K | $96.8K |
| Jan 7, 2026 | Joseph Oliveto KEY 10b5-1 | Sell S | 500 | $1.1K |
| Jan 2, 2026 | Stuart Duty | Grant A | 40.0K | $0 |
| Dec 15, 2025 | Jeffrey Edward Nelson | Sell S | 58.0K | $134.6K |
| Dec 15, 2025 | Lorenz Muller | Sell S | 53.6K | $124.3K |
| Dec 15, 2025 | Joseph Oliveto KEY | Sell S | 133.1K | $308.7K |
| Dec 15, 2025 | Amit Hasija KEY | Sell S | 58.0K | $134.6K |
| Dec 15, 2025 | David Bharucha | Sell S | 58.0K | $134.6K |
| Dec 12, 2025 | Jeffrey Edward Nelson | Grant A | 100.0K | $0 |
| Dec 12, 2025 | Jeffrey Edward Nelson | Grant A | 100.0K | — |
| Dec 12, 2025 | Lorenz Muller | Grant A | 100.0K | $0 |
| Dec 12, 2025 | Lorenz Muller | Grant A | 100.0K | — |
| Dec 12, 2025 | Joseph Oliveto KEY | Grant A | 280.0K | $0 |
| Dec 12, 2025 | Joseph Oliveto KEY | Grant A | 280.0K | — |
| Dec 12, 2025 | Amit Hasija KEY | Grant A | 100.0K | $0 |
| Dec 12, 2025 | Amit Hasija KEY | Grant A | 100.0K | — |
| Dec 12, 2025 | David Bharucha | Grant A | 100.0K | $0 |
| Dec 12, 2025 | David Bharucha | Grant A | 100.0K | — |
About MIST insider trading
This page tracks insider transactions for Milestone Pharmaceuticals Inc. (MIST) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.